Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Date first appeared online	17/01/2017
DOI	10.1016/s2213-8587(17)30013-x
Authors	Bain S.
Journal Name	The Lancet Diabetes & Endocrinology
Volume	5

Documents

• Sorli2017.pdf , Book, Released under the terms of a Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND).